# Phase 2 Inflammatory Bowel Diseases trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 2 for Inflammatory Bowel Diseases that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Inflammatory Bowel Diseases trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/inflammatory-bowel-diseases

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07942766 | A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD) | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Phase 2 | Not yet recruiting | Inflammatory Bowel Disease (IBD) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07942766) |
| September 29, 2026 | NCT07845487 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845487) |
| September 22, 2026 | NCT07832435 | A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures | Redx Pharma Ltd | Phase 2 | Not yet recruiting | Strictures Due to Crohn's Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832435) |
| September 11, 2026 | NCT07814456 | Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors | First Affiliated Hospital of Kunming Medical University | Phase 2 | Recruiting | Ulcerative Colitis (UC), Inflammatory Bowel Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814456) |
| April 6, 2026 | NCT07513181 | Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely... | Athos Therapeutics Inc | Phase 2 | Recruiting | Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513181) |
| March 17, 2026 | NCT07477782 | Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477782) |
| February 24, 2026 | NCT07431606 | Duloxetine in Inflammatory Bowel Diseases | University of Pennsylvania | Phase 2 | Recruiting | Inflammatory Bowel Diseases | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431606) |
| January 27, 2026 | NCT07368972 | Study of DISC-0974-201 in Participants With IBD and Anemia | Disc Medicine, Inc | Phase 2 | Recruiting | Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368972) |
| January 16, 2026 | NCT07349472 | Pentoxifylline in Patients With Ulcerative Colitis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Inflammatory Bowel Diseases | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349472) |
| December 5, 2025 | NCT07265570 | Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) | InSilico Medicine Hong Kong Limited | Phase 2 | Recruiting | Ulcerative Colitis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265570) |
| August 8, 2025 | NCT07113522 | A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease | Mirador Therapeutics, Inc. | Phase 2 | Recruiting | Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07113522) |
| July 22, 2025 | NCT07077746 | HB-adMSCs for the Treatment of Crohn's Disease | Hope Biosciences Research Foundation | Phase 2 | Recruiting | Crohn Disease (CD) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077746) |
| June 10, 2025 | NCT07012395 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Spyre Therapeutics, Inc. | Phase 2 | Recruiting | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07012395) |
| February 27, 2025 | NCT06850727 | Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis | Odyssey Therapeutics, Inc. | Phase 2 | Recruiting | Ulcerative Colitis (UC), UC - Ulcerative Colitis | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06850727) |
| November 21, 2024 | NCT06699121 | A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC | LISCure Biosciences | Phase 2 | Recruiting | Primary Sclerosing Cholangitis (PSC) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699121) |
| September 19, 2024 | NCT06599658 | COVID-19 Booster and IIV Schedule in Immunocompromised Hosts | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 | Recruiting | COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus, Inflammatory Bowel Disease, Solid Organ... | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06599658) |
| June 11, 2024 | NCT06453317 | Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis | Medical University of Lodz | Phase 2 | Recruiting | Ulcerative Colitis, Inflammatory Bowel Diseases | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06453317) |
| February 29, 2024 | NCT06286709 | FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis | University of Birmingham | Phase 2 | Recruiting | Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06286709) |
| January 26, 2024 | NCT06226883 | A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Phase 2 | Recruiting | Inflammatory Bowel Diseases, Crohn's Disease | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226883) |
| May 25, 2023 | NCT05876182 | Vancomycin in Primary Sclerosing Cholangitis in Italy | University of Milano Bicocca | Phase 2 | Recruiting | Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder, IBD | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05876182) |
| October 10, 2022 | NCT05574387 | Metformin as Added on Therapy in Patients With Ulcerative Colitis | Tanta University | Phase 2 | Recruiting | Inflammatory Bowel Diseases | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05574387) |
| May 6, 2019 | NCT03938701 | Fluorescence Imaging of IBD and RA Using Adalimumab-800CW | University Medical Center Groningen | Phase 2 | Recruiting | IBD, Rheumatoid Arthritis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03938701) |
| July 17, 2017 | NCT03219359 | Autologous Stem Cell Transplant for Crohn's Disease | Sponsor not shown (see the record) | Phase 2 | Recruiting | Crohn Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03219359) |
| October 14, 2013 | NCT01962415 | Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | Sponsor not shown (see the record) | Phase 2 | Recruiting | Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01962415) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Spyre Therapeutics, Inc. | 1 |
| First Affiliated Hospital of Kunming Medical University | 1 |
| University of Milano Bicocca | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 1 |
| [Hope Biosciences Research Foundation](https://specstream.ai/data/clinical-trials/company/hope-biosciences-research-foundation) | 1 |
| Redx Pharma Ltd | 1 |
| Tanta University | 1 |
| Mirador Therapeutics, Inc. | 1 |
| Disc Medicine, Inc | 1 |
| University Medical Center Groningen | 1 |
| University of Birmingham | 1 |
| Athos Therapeutics Inc | 1 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| Medical University of Lodz | 1 |
| University of Pennsylvania | 1 |
| LISCure Biosciences | 1 |
| Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 1 |
| Odyssey Therapeutics, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| Canada | 6 |
| Poland | 5 |
| China | 4 |
| Czechia | 4 |
| France | 4 |
| Georgia | 4 |
| Italy | 4 |
| Moldova | 4 |
| Australia | 3 |
| Austria | 3 |
| Hungary | 3 |
| Romania | 3 |
| Serbia | 3 |
| Slovakia | 3 |
| Ukraine | 3 |
| Bosnia and Herzegovina | 2 |
| Brazil | 2 |
| Bulgaria | 2 |
| Croatia | 2 |
| Germany | 2 |
| India | 2 |
| Japan | 2 |
| Jordan | 2 |
| Lithuania | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Gutter contractors in the United States](https://specstream.ai/data/businesses/gutter-contractors/united-states)
- [Law firms in the United States](https://specstream.ai/data/businesses/law-firms/united-states)
- [Packaging companies in the United States](https://specstream.ai/data/businesses/packaging-companies/united-states)
- [Rehabilitation centers in the United States](https://specstream.ai/data/businesses/rehabilitation-centers/united-states)
- [Textile mills in the United States](https://specstream.ai/data/businesses/textile-mills/united-states)
- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
